{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:58:40Z","timestamp":1785481120953,"version":"3.56.0"},"reference-count":41,"publisher":"American Chemical Society (ACS)","issue":"18","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI146387"],"award-info":[{"award-number":["AI146387"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI158612"],"award-info":[{"award-number":["AI158612"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI171824"],"award-info":[{"award-number":["AI171824"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM107550"],"award-info":[{"award-number":["GM107550"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI158612"],"award-info":[{"award-number":["R01AI158612"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","award":["940892"],"award-info":[{"award-number":["940892"]}],"id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["846688"],"award-info":[{"award-number":["846688"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["200018\/2023-0"],"award-info":[{"award-number":["200018\/2023-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Proteasome inhibitors are effective in treating hematologic cancers but have limited utility in brain tumors due to poor blood\u2013brain barrier (BBB) penetration and metabolic instability. In this study, we developed novel macrocyclic peptide epoxyketone inhibitors with improved drug-like properties. Compounds were screened for cytotoxicity against brain cancer cell lines, permeability (PAMPA-BBB and Caco-2), and metabolic stability. Lead compound 10 demonstrated potent in vitro activity (IC50 &amp;lt; 100 nM), low P-gp efflux, and favorable microsomal and plasma stability. In vivo pharmacokinetic studies in mice showed that compound 10 maintained therapeutic plasma levels and achieved measurable brain concentrations without toxicity. Co-administration of a P-gp inhibitor significantly enhanced brain exposure of compound 35, confirming efflux as a key parameter. The incorporation of fluorinated phenyl and \u03b1,\u03b1-dimethylglycine moieties contributed to improved BBB permeability and metabolic stability. These findings support further development of macrocyclic epoxyketone inhibitors as promising candidates for brain cancer therapy.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c00544","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T03:52:48Z","timestamp":1757389968000},"page":"18908-18929","source":"Crossref","is-referenced-by-count":3,"title":["Development\nof Macrocyclic Peptide-Based Proteasome\nInhibitors with Enhanced Blood-Brain Barrier Penetration for Treating\nBrain Neoplasms"],"prefix":"10.1021","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-0846","authenticated-orcid":true,"given":"Jehad","family":"Almaliti","sequence":"first","affiliation":[{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]},{"name":"The University of Jordan , , ,","place":["Amman, Jordan, 11942"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momen","family":"Al-Hindy","sequence":"additional","affiliation":[{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavla","family":"Fajtova\u0301","sequence":"additional","affiliation":[{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Glukhov","sequence":"additional","affiliation":[{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Berger","sequence":"additional","affiliation":[{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Graf","sequence":"additional","affiliation":[{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8153-1190","authenticated-orcid":true,"given":"Cesar Emiliano","family":"Hoffmann da Silva","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul , , , ,","place":["Porto Alegre, RS, Brazil, 90610-000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandler","family":"Huang","sequence":"additional","affiliation":[{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8957-2172","authenticated-orcid":true,"given":"Narek","family":"Azizyan","sequence":"additional","affiliation":[{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"He","sequence":"additional","affiliation":[{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5695-0409","authenticated-orcid":true,"given":"Anthony J.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1403-4458","authenticated-orcid":true,"given":"William H.","family":"Gerwick","sequence":"additional","affiliation":[{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]},{"name":"University of California San Diego , , , ,","place":["La Jolla, California, United States, 92093"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"issue":"1","key":"2026073102140241600_cit1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd3321","article-title":"Ubiquitin-like\nProtein Conjugation and the Ubiquitin\u2013Proteasome System as\nDrug Targets","volume":"10","author":"Bedford","year":"2011","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"7","key":"2026073102140241600_cit2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nrd2056","article-title":"Drug Discovery\nin the Ubiquitin\u2013Proteasome\nSystem","volume":"5","author":"Nalepa","year":"2006","journal-title":"Nat. Rev. Drug Discovery 2006 57"},{"key":"2026073102140241600_cit3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-12-397863-9.00003-1","article-title":"Immunoproteasomes:\nStructure, Function, and Antigen\nPresentation","volume":"109","author":"Ferrington","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"7","key":"2026073102140241600_cit4","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3390\/molecules27072201","article-title":"Revisiting\nProteasome Inhibitors: Molecular Underpinnings of Their Development,\nMechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug\nResistance","volume":"27","author":"Leonardo-Sousa","year":"2022","journal-title":"Molecules"},{"key":"2026073102140241600_cit5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ejmech.2018.10.024","article-title":"Exploration of the\nCarmaphycins as\nPayloads in Antibody Drug Conjugate Anticancer Agents","volume":"161","author":"Almaliti","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"2026073102140241600_cit6","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/acscentsci.7b00252","article-title":"The Proteasome in Modern Drug Discovery:\nSecond Life\nof a Highly Valuable Drug Target","volume":"3","author":"Cromm","year":"2017","journal-title":"ACS Cent.\nSci."},{"issue":"5","key":"2026073102140241600_cit7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.chembiol.2011.02.015","article-title":"Specific Cell-Permeable Inhibitor\nof Proteasome Trypsin-like\nSites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib","volume":"18","author":"Mirabella","year":"2011","journal-title":"Chem. Biol."},{"issue":"5","key":"2026073102140241600_cit8","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.ijrobp.2018.01.001","article-title":"Phase 2 Study of Bortezomib\nCombined With Temozolomide and Regional Radiation Therapy for Upfront\nTreatment of Patients With Newly Diagnosed Glioblastoma Multiforme:\nSafety and Efficacy Assessment","volume":"100","author":"Kong","year":"2018","journal-title":"Int. J. Radiat.\nOncol. Biol. Phys."},{"issue":"6","key":"2026073102140241600_cit9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/cbic.201200007","article-title":"The Carmaphycins:\nNew Proteasome Inhibitors Exhibiting an \u03b1,\u03b2-Epoxyketone\nWarhead from a Marine Cyanobacterium","volume":"13","author":"Pereira","year":"2012","journal-title":"ChemBioChem."},{"issue":"5","key":"2026073102140241600_cit10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41589-022-00993-w","article-title":"Enzymatic Assembly\nof the Salinosporamide \u03b3-Lactam-\u03b2-Lactone Anticancer Warhead","volume":"18","author":"Bauman","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"2026073102140241600_cit11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/anie.200390115","article-title":"Salinosporamide A:\nA Highly Cytotoxic Proteasome Inhibitor\nfrom a Novel Microbial Source, a Marine Bacterium of the New Genus\nSalinospora","volume":"42","author":"Feling","year":"2003","journal-title":"Angew. Chemie - Int. Ed."},{"key":"2026073102140241600_cit12","doi-asserted-by":"publisher","first-page":"9346","DOI":"10.1002\/anie.201000728","article-title":"Salinosporamide Natural Products: Potent 20 S Proteasome\nInhibitors as Promising Cancer Chemotherapeutics","volume":"3","author":"Gulder","year":"2010","journal-title":"Angew. Chem., Int. Ed."},{"issue":"18","key":"2026073102140241600_cit13","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-15-2616","article-title":"Phase I Clinical Trial of Marizomib (NPI-0052) in Patients\nwith Advanced Malignancies Including Multiple Myeloma: Study NPI-0052\u2013102\nFinal Results","volume":"22","author":"Harrison","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"15_suppl","key":"2026073102140241600_cit14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2072","article-title":"EORTC 1709\/CCTG CE.8:\nA Phase III Trial of Marizomib in Combination with Standard Temozolomide-Based\nRadiochemotherapy versus Standard Temozolomide-Based Radiochemotherapy\nAlone in Patients with Newly Diagnosed Glioblastoma","volume":"37","author":"Roth","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"2026073102140241600_cit15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib Activity\nas a Single Agent in Malignant Gliomas: Ability to Cross the Blood-Brain\nBarrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro. Oncol."},{"issue":"10","key":"2026073102140241600_cit16","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/13543784.2020.1803827","article-title":"Proteasome Inhibition\nfor the Treatment of Glioblastoma","volume":"29","author":"Roth","year":"2020","journal-title":"Expert Opin.\nInvestig. Drugs"},{"issue":"2","key":"2026073102140241600_cit17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/bjh.14498","article-title":"Marizomib for Central\nNervous System-Multiple Myeloma","volume":"177","author":"Badros","year":"2017","journal-title":"Br. J. Hamaetol."},{"issue":"1","key":"2026073102140241600_cit18","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab142","article-title":"Marizomib\nAlone or in Combination with Bevacizumab\nin Patients with Recurrent Glioblastoma: Phase I\/II Clinical Trial\nData","volume":"3","author":"Bota","year":"2021","journal-title":"Neuro-oncology Adv."},{"issue":"10","key":"2026073102140241600_cit19","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1021\/jacs.8b13178","article-title":"Macrocyclic\nPeptides as Drug Candidates: Recent Progress\nand Remaining Challenges","volume":"141","author":"Vinogradov","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"2026073102140241600_cit20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nchembio.1907","article-title":"A Biomimetic Approach for Enhancing\nthe in Vivo Half-Life of Peptides","volume":"11","author":"Penchala","year":"2015","journal-title":"Nat. Chem.\nBiol."},{"issue":"44","key":"2026073102140241600_cit21","doi-asserted-by":"publisher","first-page":"24035","DOI":"10.1021\/jacs.3c07145","article-title":"Validation of a New Methodology to\nCreate Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets","volume":"145","author":"Ohta","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"2026073102140241600_cit22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/ejh.12749","article-title":"A Practical Review on Carfilzomib\nin Multiple Myeloma","volume":"96","author":"Muchtar","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"2026073102140241600_cit23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01481-w","article-title":"The Blood\u2013Brain Barrier: Structure,\nRegulation, and Drug Delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct.\nTarget. Ther. 2023 81"},{"issue":"15","key":"2026073102140241600_cit24","doi-asserted-by":"publisher","first-page":"6718","DOI":"10.1021\/jm500786c","article-title":"Synthesis and\nin Vitro Evaluation of BBB Permeability, Tumor Cell Uptake, and Cytotoxicity\nof a Series of Carboranylporphyrin Conjugates","volume":"57","author":"Bhupathiraju","year":"2014","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026073102140241600_cit25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-41427-y","article-title":"Genetically Encoded Discovery of\nPerfluoroaryl Macrocycles That Bind to Albumin and Exhibit Extended\nCirculation in Vivo","volume":"14","author":"Wong","year":"2023","journal-title":"Nat. Commun. 2023 141"},{"issue":"6","key":"2026073102140241600_cit26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/00005072-198511000-00005","article-title":"Establishment and\nCharacterization of the Human Medulloblastoma Cell Line and Transplantable\nXenograft D283 Med","volume":"44","author":"Friedman","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2026073102140241600_cit27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.15586\/codon.glioblastoma.2017.ch15","article-title":"Pediatric Glioblastoma","author":"KANTI DAS","year":"2017","journal-title":"Glioblastoma"},{"issue":"7","key":"2026073102140241600_cit28","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1021\/jm970530e","article-title":"Physicochemical\nHigh Throughput Screening:\nParallel Artificial Membrane Permeation Assay in the Description of\nPassive Absorption Processes","volume":"41","author":"Kansy","year":"1998","journal-title":"J. Med. Chem."},{"issue":"44","key":"2026073102140241600_cit29","doi-asserted-by":"publisher","first-page":"15628","DOI":"10.1021\/jacs.7b09790","article-title":"Perfluoroarene-Based\nPeptide Macrocycles to Enhance\nPenetration Across the Blood-Brain Barrier","volume":"139","author":"Fadzen","year":"2017","journal-title":"J. Am. Chem. Soc."},{"issue":"17","key":"2026073102140241600_cit30","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.1002\/anie.202015845","article-title":"Development of a Highly Selective\nPlasmodium Falciparum Proteasome Inhibitor with Anti-Malaria Activity\nin Humanized Mice","volume":"60","author":"Zhan","year":"2021","journal-title":"Angew. Chemie Int. Ed."},{"key":"2026073102140241600_cit31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jconrel.2022.10.051","article-title":"A Pt(IV)-Conjugated Brain Penetrant Macrocyclic Peptide\nShows Pre-Clinical Efficacy in Glioblastoma","volume":"352","author":"Jimenez-Macias","year":"2022","journal-title":"J. Controlled Release"},{"key":"2026073102140241600_cit32","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","article-title":"Group, for the E. B. T. G. and the\nC. C. T. Marizomib for Patients with Newly Diagnosed Glioblastoma:\nA Randomized Phase 3 Trial","volume":"26","author":"Roth","year":"2024","journal-title":"Neuro. Oncol."},{"issue":"2","key":"2026073102140241600_cit33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1517\/17425255.1.2.175","article-title":"Caco-2 Cell Permeability Assays to\nMeasure Drug Absorption","volume":"1","author":"Van Breemen","year":"2005","journal-title":"Expert Opin. Drug Metab.\nToxicol."},{"issue":"2","key":"2026073102140241600_cit34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1021\/acsptsci.0c00200","article-title":"Inhibition of P-Glycoprotein\nDoes Not Increase the\nEfficacy of Proteasome Inhibitors in Multiple Myeloma Cells","volume":"4","author":"Mynott","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"2","key":"2026073102140241600_cit35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.chembiol.2016.12.016","article-title":"Inhibition of the\nProteasome \u03922 Site Sensitizes\nTriple-Negative Breast Cancer Cells to \u03925 Inhibitors through\na Mechanism Involving Nrf1 Suppression","volume":"24","author":"Weyburne","year":"2017","journal-title":"Cell\nChem. Biol."},{"issue":"1","key":"2026073102140241600_cit36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-31400-6","article-title":"The Cytotoxic\nActivity of Carfilzomib Together with Nelfinavir Is Superior to the\nBortezomib\/Nelfinavir Combination in Non-Small Cell Lung Carcinoma","volume":"13","author":"Besse","year":"2023","journal-title":"Sci. Reports 2023 131"},{"issue":"7","key":"2026073102140241600_cit37","first-page":"3280","article-title":"Bortezomib- and Carfilzomib-Resistant Myeloma Cells\nShow Increased Activity of All Three Arms of the Unfolded Protein\nResponse","volume":"12","author":"Kubicki","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"5","key":"2026073102140241600_cit38","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40262-023-01242-6","article-title":"Mechanistic Pharmacokinetic\/Pharmacodynamic\nModeling in Support of a Patient-Convenient, Longer Dosing Interval\nfor Carfilzomib, a Covalent Inhibitor of the Proteasome","volume":"62","author":"Yago","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"2026073102140241600_cit39","doi-asserted-by":"publisher","first-page":"9676","DOI":"10.3390\/curroncol30110702","article-title":"Proteasome\nInhibitors against Glioblastoma-Overview of Molecular Mechanisms of\nCytotoxicity, Progress in Clinical Trials, and Perspective for Use\nin Personalized Medicine","volume":"30","author":"Gozdz","year":"2023","journal-title":"Curr. Oncol."},{"issue":"1","key":"2026073102140241600_cit40","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa021","article-title":"Bortezomib at Therapeutic Doses Poorly Passes the Blood-Brain\nBarrier and Does Not Impair Cognition","volume":"2","author":"Huehnchen","year":"2020","journal-title":"Brain\nCommun."},{"issue":"9","key":"2026073102140241600_cit41","doi-asserted-by":"publisher","first-page":"7146","DOI":"10.1021\/acs.jmedchem.3c02488","article-title":"Brain-Permeable\nImmunoproteasome-Targeting Macrocyclic Peptide Epoxyketones for Alzheimer\u2019s\nDisease","volume":"67","author":"Park","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c00544","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/18\/18908\/66295364\/acs.jmedchem.5c00544.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/18\/18908\/66295364\/acs.jmedchem.5c00544.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:14:08Z","timestamp":1785478448000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/18\/18908\/5234809\/Development-of-Macrocyclic-Peptide-Based"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":41,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9,8]]},"published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00544","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}